Vous avez cherché: boostera (Croate - Anglais)

prije boostera
pre-booster

1 mjesec nakon boostera
1 month after booster

21-28 dana nakon boostera
21-28 days post booster

vrlo često: proljev, povraćanje (manje često nakon boostera)
very common: diarrhoea, vomiting (uncommon after booster)

1., 2. ili boostera) bila je slična i navedena je kako slijedi:
1st, 2nd or booster) were similar and are listed according to the following frequency:

ovaj dio opisuje kliničko iskustvo s cjepivom aflunov nakon primjene dviju doza i boostera.
this section describes the clinical experience with aflunov following a two-dose administration and booster.

1., 2. ili boostera) bile su slične i navedene su prema sljedećoj učestalosti:
1st, 2nd or booster) were similar and are listed according to the following frequency:

manje često: bljedoća (rijetko nakon boostera) rijetko: kawasakijev sindrom
uncommon: pallor (rare after booster) rare: kawasaki syndrome

odgovori serumskih baktericidnih protutijela nakon boostera 12 mjeseci nakon primarnog cijepljenja provedenog u dobi od 2, 3 i 4 ili 2, 4 i 6 mjeseci i postojanost baktericidnih protutijela jednu godinu nakon boostera
serum bactericidal antibody responses following a booster at 12 months after a primary series administered at 2, 3 and 4 or 2, 4 and 6 months of age, and persistence of bactericidal antibody one year after the booster

vremenska točka prije boostera pokazuje postojanost baktericidnih protutijela 8 mjeseci nakon cijepljenja bexserom u dobi od 2, 3 i 4 mjeseca i 6 mjeseci nakon cijepljenja bexserom u dobi od 2, 4 i 6 mjeseci.
pre-booster time point represents persistence of bactericidal antibody at 8 months after bexsero vaccination at 2, 3 and 4 months of age and 6 months after bexsero vaccination at 2, 4 and 6 months of age.

nakon 12-mjesečnog booster-cijepljenja odobrenim trivalentnim virosomnim cjepivom protiv influence za sezonu gripe sjeverne hemisfere 2010./2011., stupnjevi serozaštite, stupnjevi serokonverzije i čimbenici serokonverzije (u usporedbi s razinama protutijela prije boostera) za sastojak h1n1 izmjereni srh i mn analizama bili su sljedeći:
following a 12-month booster vaccination with a licensed trivalent virosomal influenza vaccine for the 2010/2011 northern hemisphere influenza season, seroprotection rates, seroconversion rates and serconversion factors (compared to pre-booster antibody levels) for the h1n1 component as measured by srh and mn assays were as follows: